Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Entschladen

Showing results (1-10 of 56) with videos related to

Pageof 6
Sort By:
Advances in Biochemical Engineering/Biotechnology|August 18, 2012
Migratory properties of mesenchymal stem cellsThomas Dittmar, Frank Entschladen
Progress in Experimental Tumor Research|February 23, 2007
Neoneurogenesis and the neuro-neoplastic synapseDaniel Palm, Frank Entschladen
Cell Communication and Signaling : CCS|December 6, 2008
Extravasation of leukocytes in comparison to tumor cellsCarina Strell, Frank Entschladen
Recent Patents on Anti-Cancer Drug Discovery|June 13, 2009
Paving roads for new drugs in oncologyKurt S Zaenker, Frank Entschladen
Cell Communication and Signaling : CCS|September 9, 2010
Tumor interactions with soluble factors and the nervous systemMelanie J Voss, Frank Entschladen
Nature Reviews. Clinical Oncology|August 3, 2011
Targeted therapies: Using β-blockers to inhibit breast cancer progressionDesmond G Powe, Frank Entschladen
Cell Cycle (Georgetown, Tex.)|March 25, 2011
Heterotrimeric G protein signaling in cancer cells with regard to metastasis formationFrank Entschladen, Kurt S Zänker, Desmond G Powe
Current Pharmaceutical Design|June 6, 2012
Translational research in oncology: the need of additional in vitro preclinical testing methods for new drugsTheodore L Drell, Kurt S Zanker, Frank Entschladen
Cells|January 16, 2016
Re-Use of Established Drugs for Anti-Metastatic IndicationsFrank Entschladen, Dane A Thyssen, David W Drell
Cancer Immunology, Immunotherapy : CII|March 23, 2004
Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytesJan Joseph, Bernd Niggemann, Kurt S Zaenker, et al.
Pageof 6

Showing results (1-10 of 56) with videos related to

Sort By:
Pageof 6
Advances in Biochemical Engineering/Biotechnology|August 18, 2012
Migratory properties of mesenchymal stem cellsThomas Dittmar, Frank Entschladen
Progress in Experimental Tumor Research|February 23, 2007
Neoneurogenesis and the neuro-neoplastic synapseDaniel Palm, Frank Entschladen
Cell Communication and Signaling : CCS|December 6, 2008
Extravasation of leukocytes in comparison to tumor cellsCarina Strell, Frank Entschladen
Recent Patents on Anti-Cancer Drug Discovery|June 13, 2009
Paving roads for new drugs in oncologyKurt S Zaenker, Frank Entschladen
Cell Communication and Signaling : CCS|September 9, 2010
Tumor interactions with soluble factors and the nervous systemMelanie J Voss, Frank Entschladen
Nature Reviews. Clinical Oncology|August 3, 2011
Targeted therapies: Using β-blockers to inhibit breast cancer progressionDesmond G Powe, Frank Entschladen
Cell Cycle (Georgetown, Tex.)|March 25, 2011
Heterotrimeric G protein signaling in cancer cells with regard to metastasis formationFrank Entschladen, Kurt S Zänker, Desmond G Powe
Current Pharmaceutical Design|June 6, 2012
Translational research in oncology: the need of additional in vitro preclinical testing methods for new drugsTheodore L Drell, Kurt S Zanker, Frank Entschladen
Cells|January 16, 2016
Re-Use of Established Drugs for Anti-Metastatic IndicationsFrank Entschladen, Dane A Thyssen, David W Drell
Cancer Immunology, Immunotherapy : CII|March 23, 2004
Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytesJan Joseph, Bernd Niggemann, Kurt S Zaenker, et al.
Pageof 6